Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits
Du Pasquier, Renaud A.
MetadataShow full item record
CitationPerrotta, G., G. Bonnier, D. Meskaldji, D. Romascano, R. Aydarkhanov, A. Daducci, S. Simioni, et al. 2017. “Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.” Annals of Clinical and Translational Neurology 4 (12): 915-920. doi:10.1002/acn3.493. http://dx.doi.org/10.1002/acn3.493.
AbstractAbstract Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34868920
- HMS Scholarly Articles